Renal & Urology News4d
Gepotidacin Gets Priority Review for Uncomplicated UTI in Female Patients
The FDA granted Priority Review to gepotidacin for the treatment of female adults and adolescents with uncomplicated UTI.
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
The FDA accepts and grants priority review to GSK's NDA for gepotidacin for treating uncomplicated urinary tract infections. A decision is due on March 26, 2025.
pharmaphorum1d
FDA set to decide on GSK's gepotidacin antibiotic in March
The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in over 20 years.
GSK Seeks FDA Approval For Oral Antibiotic For Urinary Tract Infections, Probably First In New Class In Over 20 Years
On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an ...
Nasdaq5d
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
GSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, first-in-class oral antibiotic, gepotidacin for treating uncomplicated ...
Pharmabiz6d
US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents
US FDA accepts for priority review GSK’s NDA for gepotidacin to treat uncomplicated urinary tract infections in female adults and adolescents: London, UK Thursday, October 17, 2 ...
PMLiVE5d
GSK’s investigational antibiotic granted FDA priority review for urinary tract infections
GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the ...